A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine TumorsSandip Pravin Patel, Razelle Kurzrock, Annette Campbell Fontaine et al.|Clinical Cancer Research|2020Cited by 326
Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profilingStacey Gargano, Zoran Gatalica|Cancer Medicine|2019Cited by 54
A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational StudyStanley Cohen, Viatcheslav R. Akmaev, Alvin F. Wells et al.|Rheumatology and Therapy|2021Cited by 34